Physician profile
Lydia E Moore
NPI 1982059317
$4,393.55
in general payments reported to CMS, 2019-2025
16 companies · $616 in 2025
The $616 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $928 · 2022: $905 · 2023: $929 · 2024: $1,016 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,561.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,545.07 | 2021-2025 | Watchman Flx, Watchman Access System, Cds - Mct/Cem Monitoring |
| Janssen Pharmaceuticals, INC | $665.37 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.19 | 2021-2024 | Jardiance |
| Abbott Laboratories | $139.01 | 2023-2024 | Assurity, Cardiomems |
| Medtronic, INC. | $138.08 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $128.83 | 2021-2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $121.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $101.83 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $69.18 | 2023-2025 | Winrevair, Verquvo |
| Edwards Lifesciences Corporation | $68.21 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $54.72 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $52.39 | 2022-2023 | Farxiga |
| Amgen INC. | $51.95 | 2021-2023 | Repatha |
| Biotronik INC. | $48.64 | 2022-2024 | Amvia Edge |
| Kiniksa Pharmaceuticals, LTD. | $40.22 | 2023 | Arcalyst |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.